12933_2017_529_MOESM1_ESM.doc (379 kB)
MOESM1 of Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
journal contribution
posted on 2017-04-04, 05:00 authored by Gian Fadini, Benedetta Bonora, Giancarlo Zatti, Nicola Vitturi, Elisabetta Iori, Maria Marescotti, Mattia Albiero, Angelo AvogaroAdditional file 1. Supplemental data on cholesterol efflux capacity and bioimpedance vector analysis.